FDA approves oveporexton, the first orexin receptor agonist, for narcolepsy type 1

The US Food and Drug Administration approved Orzeyful (oveporexton) on 5 August 2026 for narcolepsy type 1 in adults. It is the first medicine that restores orexin signalling directly, by activating the brain receptor for the neuropeptide that patients with narcolepsy type 1 have lost, and the first drug to treat the underlying biology of the disease rather than its individual symptoms. It arrives twenty-seven years after the link between orexin and narcolepsy was discovered.

Narcolepsy type 1 is caused by the autoimmune destruction of the roughly 70,000 hypothalamic neurons that make orexin. Every previously approved therapy treated sleepiness or cataplexy symptomatically. Oveporexton is a selective orexin receptor 2 agonist, given as an oral tablet twice daily. The sponsor is Takeda Pharmaceuticals America, Inc., and the product was approved under priority review as application NDA 220860, according to the Drugs@FDA record. Safety and efficacy have not been established in patients under 18.

Tiffany R. Farchione, M.D., Director of the Division of Psychiatry in the FDA's Center for Drug Evaluation and Research, said: "This new drug is the first medicine that impacts the underlying biology of the disease, treating narcolepsy type 1 as a whole."

The registrational evidence, according to the FDA, comprises two randomised, double-blind, placebo-controlled 12-week studies in a combined 273 adults with narcolepsy type 1. They are First Light (NCT06470828), which enrolled 168 participants randomised 3:3:2 to oveporexton 1 mg, 2 mg or placebo twice daily, and Radiant Light (NCT06505031), which enrolled 105 randomised 2:1 to 2 mg or placebo. Full phase 3 results were published in the New England Journal of Medicine on 9 September 2026 as “Oveporexton for Narcolepsy Type 1 — Results from Two Phase 3 Trials”, under DOI 10.1056/NEJMoa2601598, with PubMed identifier 42714024.

The primary endpoint was the change from baseline to week 12 in mean sleep latency on the Maintenance of Wakefulness Test, which runs from 0 to 40 minutes, with 20 minutes or above regarded as normal. Improvements ranged from 14.3 to 19.8 minutes with oveporexton, against minus 0.4 to minus 0.8 minutes with placebo, with adjusted P less than 0.001 for all comparisons. Epworth Sleepiness Scale total scores, on a range of 0 to 24 where below 10 is normal, changed by minus 9.7 to minus 11.8 with oveporexton, against minus 1.5 to minus 1.7 with placebo, again with adjusted P less than 0.001 for all comparisons. The weekly cataplexy rate fell by a median of 79.0 to 88.8 per cent with oveporexton, versus 27.7 to 39.1 per cent with placebo, with adjusted P less than 0.001 for all comparisons.

On safety, adverse events occurred in 86 to 89 per cent of participants given oveporexton and in 43 to 54 per cent of those given placebo. The most common were increased urinary frequency and transient insomnia, each affecting a majority of treated participants. The FDA also lists increased saliva production. The drug is contraindicated with strong CYP3A inhibitors.

The New England Journal of Medicine paper was led by Yves Dauvilliers of the Sleep-Wake Disorders Center at Gui-de-Chauliac Hospital and the Institute for Neurosciences of Montpellier, INSERM, University of Montpellier, with Emmanuel Mignot of the Stanford Center for Sleep Sciences and Medicine as second author. Investigators were based in France, Poland, Belgium, Spain, Switzerland, the Netherlands, Germany, Norway, Italy, Australia, Japan and China. The trials were funded by Takeda Development Center Americas.

There is a symmetry to the timing. Mignot shared the 2026 Albert Lasker Basic Medical Research Award for discovering the orexin basis of narcolepsy. That award was announced on 9 September 2026, the same day the phase 3 paper appeared.

The FDA granted oveporexton Breakthrough Therapy designation and priority review. Marketing becomes lawful only once the Drug Enforcement Administration issues its scheduling decision under the Controlled Substances Act.